248 related articles for article (PubMed ID: 15739896)
1. Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: ether derivatives.
Apelt J; Grassmann S; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
Pharmazie; 2005 Feb; 60(2):97-106. PubMed ID: 15739896
[TBL] [Abstract][Full Text] [Related]
2. Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities.
Grassmann S; Apelt J; Sippl W; Ligneau X; Pertz HH; Zhao YH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
Bioorg Med Chem; 2003 May; 11(10):2163-74. PubMed ID: 12713826
[TBL] [Abstract][Full Text] [Related]
3. Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity.
Apelt J; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
J Med Chem; 2002 Feb; 45(5):1128-41. PubMed ID: 11855993
[TBL] [Abstract][Full Text] [Related]
4. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
5. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives.
Grassmann S; Apelt J; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
Arch Pharm (Weinheim); 2004 Oct; 337(10):533-45. PubMed ID: 15476285
[TBL] [Abstract][Full Text] [Related]
6. Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy)alkyl)-1H-imidazole structure.
Stark H; Hüls A; Ligneau X; Purand K; Pertz H; Arrang JM; Schwartz JC; Schunack W
Arch Pharm (Weinheim); 1998 Jun; 331(6):211-8. PubMed ID: 9713254
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
8. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Gbahou F; Vincent L; Humbert-Claude M; Tardivel-Lacombe J; Chabret C; Arrang JM
Br J Pharmacol; 2006 Apr; 147(7):744-54. PubMed ID: 16432504
[TBL] [Abstract][Full Text] [Related]
9. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
[TBL] [Abstract][Full Text] [Related]
10. Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists.
Łazewska D; Ligneau X; Schwartz JC; Schunack W; Stark H; Kieć-Kononowicz K
Bioorg Med Chem; 2006 May; 14(10):3522-9. PubMed ID: 16466921
[TBL] [Abstract][Full Text] [Related]
11. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
[TBL] [Abstract][Full Text] [Related]
12. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality.
Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W
Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236
[TBL] [Abstract][Full Text] [Related]
13. Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.
Meier G; Apelt J; Reichert U; Grassmann S; Ligneau X; Elz S; Leurquin F; Ganellin CR; Schwartz JC; Schunack W; Stark H
Eur J Pharm Sci; 2001 Jun; 13(3):249-59. PubMed ID: 11384847
[TBL] [Abstract][Full Text] [Related]
14. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
[TBL] [Abstract][Full Text] [Related]
15. Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors.
Vacondio F; Mor M; Silva C; Zuliani V; Rivara M; Rivara S; Bordi F; Plazzi PV; Magnanini F; Bertoni S; Ballabeni V; Barocelli E; Carrupt PA; Testa B
Eur J Pharm Sci; 2004 Sep; 23(1):89-98. PubMed ID: 15324926
[TBL] [Abstract][Full Text] [Related]
16. Piperidine-containing histamine H3-receptor antagonists of the carbamate series: variation of the spacer length.
Łazewska D; Kieć-Kononowicz K; Pertz HH; Stark H; Schunack W; Elz S
Pharmazie; 2001 Dec; 56(12):927-32. PubMed ID: 11802653
[TBL] [Abstract][Full Text] [Related]
17. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
18. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
[TBL] [Abstract][Full Text] [Related]
19. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
20. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type.
Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T
Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
